Resource Filter: COMET™
Immune Landscape of Adenoid Cystic Carcinoma using Multiplex Immunofluorescence and Digital Pathology
Date
Optimal Antitumor Immunity is Triggered by WTX-124, a Clinical Stage Conditionally Activated INDUKINE™ Molecule that Releases Fully Potent IL-2 into the Tumor Microenvironment
Date
Development of WTX-712, a Conditionally Active IL-21 INDUKINETM Molecule for the Treatment of Cancer
Date
The Combination of ACT and INDUKINE™ Therapy Leads to Improved Antitumor Immunity in Mouse Solid Tumors
Date
Spatial Analysis of Tumor Infiltrating Lymphocyte Populations in Syngeneic Mouse Tumor Models After Treatment with IL-12 (mWTX-330) or IL-2 (WTX-124) INDUKINE™ Molecules
Date
Fully Automated Sequential Immunofluorescence (seqIF) for Hyperplex Spatial Proteomics
Date
Super-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomas
Date
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance
Date
Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by IL-6 blockade
Date
Studying the immune status of the tumor microenvironment with automated hyperplex immunofluorescence
Date
